Binding Properties of Monoclonal Antibodies against Human Fragment D-Dimer of Cross-Linked Fibrin to Human Plasma Clots in an In Vivo Model in Rabbits

Summary

Two (MA-15C5 and MA-8D3) out of approximately 500 monoclonal antibodies, obtained by fusion of P3X63-Ag8-6.5.3 myeloma cells with spleen cells of mice immunized with purified fragment D-dimer from human fibrin, demonstrated a more than 1,000-fold higher affinity for fragment D-dimer than for native fibrinogen. MA-15C5 was directed against a neoantigenic determinant only expressed in fragment D-dimer. MA-8D3 reacted equally well with fragment D-dimer of crosslinked fibrin and with fragment D of non-crosslinked fibrin but not with fragment D of fibrinogen. Both monoclonal antibodies did not crossreact with rabbit fibrin and its degradation products.

The binding of ¹²⁵I-labeled Fab fragments to human plasma clots, introduced and aged for 1 hr in the jugular vein of heparinized rabbits was studied. Following injection of an equimolar mixture of Fab fragments derived from MA-15C5 and MA-8D3, the clot to blood ratios of radioactivity increased from 3.2 ± 1.2(mean ± SD) at 4 hr to 7.2 ± 1.4 at 17 hr. The binding of Fab fragments of MA-15C5 and MA-8D3 was independent of the age (1 to 72hrs) of the clot and of heparin anticoagulation and was only slightly decreased (by 20%) in the presence of circulating human fibrinogen (90 mg/kg body weight) and of human crosslinked fibrin degradation products at a plasma concentration of 10 pg/ml. The binding of Fab fragments of MA-15C5 and MA-8D3 to occlusive human plasma clots in the femoral artery of rabbits was comparable to that of the non-occlusive human plasma clots in the jugular vein. The Fab fragments of MA-15C5 and MA-8D3, labeled with ¹²³I to a specific activity of 10 μCi/pg were injected intravenously (3 μg/kg) in 72 rabbits with a nonocclusive 0.2 ml human plasma clot in the jugular vein and in 7 control rabbits that underwent the surgical procedure without clot formation. Total body scans performed at hourly intervals revealed a higher relative increase in gamma counts over the thrombus region in the group with thrombus as compared to controls: at 6 hr 54 ± 18 vs 16 ± 13% (mean ± SEM, p <0.1) and at12 hrs 35 ± 11 vs –7 ± 12 (p <0.05). The vein segment to blood ratios of ¹²³I at 24 hrs were 6.6 ± 2.4 in the group with clot and 1.5 to 0.7 in the control group (p <0.01). We conclude that these Fab fragments may have a sufficiently high fibrin-affinity to allow in vivo thrombus localization by external scanning.

Keywords

Thrombus imaging - Fibrin - specific antibodies - Thrombosis

• References

• 1 Grossman ZD, Wistow BW, Me Afee JG. Technetium-99m-oxine and indium- 111-oxine labeled platelets II. Localization of experimentally induced vascular lesions. J Nucl Med 1978; 19: 448-491
• 2 Knight LC, Primeau JL, Siegel BA, Welch MJ. Comparison of In-111 labeled platelets and iodinated fibrinogen for the detection of deep venous thrombosis. J Nucl Med 1978; 19: 891-894
• 3 Moser KM, Spragg RG, Bender F, Konopka R, Hartman MM, Fedullo P. Study of factors that may condition scintigraphic detection of venous thrombi and pulmonary emboli with indium-lll-labeled platelets. J Nucl Med 1980; 21: 1051-1058
• 4 Dormehl IC, Jacobs DJ, du Plessis M, Pretorius JJ, Franz RC. Evaluation of the diagnostic efficacy of autologous 111-In-labeled platelets as a scanning agent for deep venous thrombosis in the chacma baboon. Eur J Nucl Med 1985; 10: 432-436
• 5 Oster SH, Srivastava SC, Som P, Meinken GG, Scudder LE, Yamamoto K, Atkins HH, Brill AB, Coller BS. Thrombus radioimmunoscintigraphy: an approach using monoclonal antiplatelet antibody. Proc Natl Acad Sci USA 1985; 82: 3465-3468
• 6 Ezekowitz MD, Coller BS, Srivastava SC. Potential application of labeled antibodies for thrombus detection. Int J Rad Appl Instrum 1986; 13: 407-411
• 7 Som P, Oster ZZ, Zamora PO, Yamamoto K, Sacker DD, Brill AB, Newell KD, Rhodes BA. Radioimmunoimaging of experimental thrombi in dogs using technetium-99m-labeled monoclonal antibody fragments reactive with human platelets. J Nucl Med 1986; 27: 1315-1320
• 8 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe E. Specificity of a monoclonal antibody for the NH₂-terminal region of fibrin. Mol Immunol 1984; 21: 89-94
• 9 Rosebrough SF, Kudryk B, Grossman ZZ, Me Afee JG, Subramanian G, Ritter-Hrncirik CC, Witanowski LS, Tillapaugh-Fay G. Radioimmunoimaging of venous thrombi using iodine-131 monoclonal antibody. Radiology 1985; 156: 515-518
• 10 Rosebrough SF, Grossman ZD, Me Afee JG, Kudryk BJ, Subramanian G, Ritter-Hrncirik CC, Witanowski LS, Tillapaugh-Fay G, Urrutia E. Aged venous thrombi: radioimmunoimaging with fibrin-specific monoclonal antibody. Radiology 1987; 162: 575-577
• 11 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Ark Kemi 1956; 10: 415
• 12 Collen D, Kudryk B, Hessel B, Blombäck B. Primary structure of human fibrinogen and fibrin. Isolation and partial characterisation of chains of fragment D J Biol Chem 1975; 250: 5808-5817
• 13 Haverkate F, Timan G. Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragment D. Thromb Res 1977; 10: 803-812
• 14 Bini A, Semeraro N, Collen D. Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and on fragment D from fibrinogen, non crosslinked or crosslinked fibrin. Thromb Res 1978; 13: 443-451
• 15 Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemostas 1987; 58: 1024-1029
• 16 Holvoet P, Lijnen HH, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. Blood 1986; 67: 1482-1487
• 17 Kearney JF, Radbruch A, Liesegang B, Rajewski K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979; 123: 1548-1550
• 18 Groth St Fazekas de, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980; 35: 1-21
• 19 Anderson PN, Potter M. Induction of plasma cell tumors in Balb/c mice with 2, 6, 10, 14 tetramethyl-pentadecane (pristane). Nature 1969; 222: 994-995
• 20 Stähli C, Miggiano V, Stocker J, Staehelin T, Häring P, Takacs B. Distinction of epitopes by monoclonal antibodies. Methods Enzymol 1983; 92: 242-253
• 21 Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgGl, IgG2a, IgG2b immunoglobulin from mouse serum using protein A Sepharose. Immunochemistry 1978; 15: 425-436
• 22 Oi VT, Herzenberg LA. Localization of murine Ig-lb and Ig-la (IgG2a) allotypic determinants detector with monoclonal antibodies. Mol Immunol 1979; 16: 1005-1017
• 23 Marchalonis JJ. An enzymatic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305
• 24 Frankel ME, Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus Mol Immunol 1979; 16: 101-106
• 25 Karush F. Immunologic specificity and molecular structure. Adv Immunol 1962; 2: 1-40
• 26 Collen D, Stassen JJ, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J Clin Invest 1983; 71: 368-376
• 27 Haber E. Monoclonal antibodies: their potential as in-vivo diagnostic and therapeutic agents. In: Monoclonal Antibodies and New Trends in Immunoassays. Bizollon CH A. (ed) Elsevier; Amsterdam: pp 81-90
• 28 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemostas 1983; 50: 591-594
• 29 Scheefers-Borchel U, Miiller-Berghaus G, Fuhge P, Eberle R, Heim-burger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095
• 30 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies of predetermined specificity for fibrin: a rational approach to monoclonal antibody production. Hybridoma 1986; 3: 215-222
• 31 Khaw BA, Haber E. Radioimmunochemical imaging of myocardial infarction: utilization of anticardiac myosin antibodies. In: Tumor Imaging: The Radioimmunochemical Detection of Cancer. Burchiel S, Rhodes BB, Friedman B. (eds) Masson Publishing; New York: 1981. p 189
• 32 Whitaker AN, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ, Bunce IH. Measurement of crosslinked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol 1984; 37: 882-887
• 33 Rowbotham BJ, Carroll P, Whitaker AA, Bunce IH, Cobcroft RG, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ. Measurement of crosslinked fibrin derivatives. Use in the diagnosis of venous thrombosis Thromb Haemostas 1987; 57: 59-61
• 34 Hashimoto Y, Stassen JJ, Leclef M, De Roo M, Vandecruys A, Melin J, Verhoeven-Mester D, Trouet A, Collen D. Thrombus imaging with¹²³I-labeled F(ab’)₂fragment of an antihuman fibrin monoclonal antibody in a rabbit thrombus model. Radiology. 1989 (in press)